Skip to content

Evaluation the effect of of ostrich oil on pain intensity and episiotomy wound healing

Evaluation the effect of of ostrich oil on pain intensity and episiotomy wound healing in primiparous women

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20231007059638N1
Enrollment
112
Registered
2024-01-28
Start date
2024-02-09
Completion date
Unknown
Last updated
2024-03-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Episiotomy.

Interventions

Intervention 1: Intervention group: Ostrich oil will be prepared in 30 gram oil tubes containing ostrich oil to be used twice a day for two centimeters on the episiotomy suture for ten days after deli

Sponsors

Shahid Beheshti University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 35 Years

Inclusion criteria

Inclusion criteria: The mother to be primiparous. Be in 18 to 35 age range. Be literate in reading and writing. Be a resident of Tehran. Be Iranian. Mother's Body Mass Index(BMI) be in 18.5 to 25 range in the beginning of pregnancy. Gestational age be 37 to 42 full weeks. Fetus be live singleton with cephalic presentation. Neonatal weight be 2500 to 4000 gr. Vaginal delivery with mediolateral episiotomy and without assisting tools(forceps, vacuum). Be 1 and 2 grade episiotomy. Do not consume cigarettes, alcohol or drugs. The episiotomy incision site be repaired by chromic cut-coat thread. free of any underlying disease that interferes with wound healing (chronic systemic, cardiopulmonary, connective tissue diseases, anemia, diabetes, malnutrition, hemophilia, mental disorders, and kidney failure) and obstetric problems such as diabetes in pregnancy, preeclampsia, eclampsia, coagulation disorders, Decollement, chorioamnionitis and immune system defects according to the person's statements and the medical/midwifery record. She has not used any drugs effective on wound healing, such as corticosteroids, anticoagulants, antiepileptics, immunosuppressants, broad-spectrum antibiotics, and chemotherapy. Rupture of membrane should not last more than 24 hours. Do not have severe anemia during pregnancy (hemoglobin less than 7). Disruption in the progress of labor and prolongation of the stages of labor (the duration of the first stage of labor more than 14 hours, the duration of the second stage more than 2 hours and the duration of the third stage more than half an hour) have not occurred. There is no history of allergy to topical and herbal medicines according to the person's statement. Don't have family conflicts and severe financial problems in the last 1 month. Don't have any history or current illness of mental disorders such as depression according to the mother's statement.

Exclusion criteria

Exclusion criteria: The person does not want to continue participating in the research. On the designated days (the fifth day and the tenth day) after delivery, he has not returned for care. Allergic to ostrich oil. He has not used the oil regularly and for more than 2 times. Having a hematoma at the episiotomy site in the first 24 hours after delivery. Having fever and puerperal infection. Having abnormal bleeding in the first 24 hours after delivery. Having severe constipation after delivery and during the study. Having hemorrhoids or anal fissure after childbirth. The baby was hospitalized during the study. Have sex in the first 10 days after giving birth. If the samples need placenta curettage.

Design outcomes

Primary

MeasureTime frame
Wound healing score. Timepoint: 1st, 5th and 10th day after delivery. Method of measurement: Perineal healing control form (REEDA).;Maternal pain intensity score. Timepoint: 1st, 5th and 10th day after delivery. Method of measurement: Visual Analog Scale (VAS).

Secondary

MeasureTime frame
-. Timepoint: -. Method of measurement: -.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSeyyede Zahra Mousavi

Shahid Beheshti University of Medical Sciences

szahra.mousavi@sbmu.ac.ir+98 21 8865 5366

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026